Inhalable bioresponsive chitosan microspheres of doxorubicin and soluble curcumin augmented drug delivery in lung cancer cells

In present investigation, doxorubicin (Dox) and soluble curcumin (Cur-2-HP-beta-CD-complex) combination was simultaneously loaded in inhalable bioresponsive chitosan microspheres (Dox/Cur2-HP-beta-CD-complex-elastin-CMs) bearing a substrate-stimuli, elastin. The mean particle size and mean aerodynamic diameter of inhalable bioresponsive microspheres displayed noteworthy differences after incorporation of elastin. Moreover, combination of Dox and soluble curcumin was molecularly dispersed in microspheres matrix as substantiated by a range of spectral techniques. Inhalable bioresponsive micro spheres released astonishingly higher amount of Dox in presence of elastase enzyme at pH similar to 5.5 in comparison to pH similar to 7.4. However, the release of soluble curcumin from tailored bioresponsive micro spheres in presence of elastase enzyme was independent of pH. Consistently, inhalable bioresponsive microspheres exhibited outstandingly lower IC50 of 3.4-mu M in comparison to 6.5-mu M of inhalable drug loaded microspheres (Dox/Cur-2-HP-beta-CD-complex-CMs) bearing no elastin, against A549, non-small cell lung cancer cells. The superior therapeutic profile of inhalable bioresponsive microspheres may be attributed to enhanced drug release and consequently augmented drug exposure to A549 cells expressing elastase enzyme. In this way, stimuli triggered drug release from tailored inhalable bioresponsive microspheres boosted the phenomena of apoptosis in A549 cells. In conclusion, Dox/Cur-2-HP-beta-CD-complex-elastin-CMs warrant further in-vivo tumor regression study to prove its therapeutic efficacy. (C) 2017 Elsevier B.V. All rights reserved.